ProNET — Predicting and Tracking Early Psychosis Risk
ProNET: Psychosis-Risk Outcomes Network
This project follows people at clinical high risk for psychosis to find patterns in brain scans, EEG, genes, body fluids, speech, and phone data that signal who may develop psychosis.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-11382679 on NIH RePORTER |
What this research studies
If you are identified as being at clinical high risk for psychosis, this network would ask you to complete detailed tests including MRI brain scans, EEG recordings, cognitive and symptom interviews, genetic and body-fluid samples, speech recordings, and passive data from smartphones. About 1,040 people at risk across 26 international sites will be followed at multiple visits over 24 months, with two timepoints for biomarker repeats, and 260 healthy volunteers will provide baseline comparison data. The study collects data at eight timepoints to track symptoms and biological changes over time and uses both standard lab measures and exploratory digital and EEG metrics. The goal is to combine these different types of information to find patterns tied to clinical outcomes during a treatment-relevant window.
Who could benefit from this research
Good fit: Ideal candidates are people identified as clinical high risk for psychosis or who have recent attenuated psychotic symptoms and are willing to take part in repeated visits and tests.
Not a fit: People without clinical high-risk features, or those who already have a long-established psychotic disorder, are unlikely to benefit directly from this particular project.
Why it matters
Potential benefit: If successful, this work could help identify who is most likely to develop psychosis and guide earlier, more personalized care to prevent or reduce illness.
How similar studies have performed: Smaller, single-site CHR studies have found some promising biomarkers, but this large, multi-site effort combining MRI, EEG, genetics, fluids, speech, and digital data is more comprehensive and relatively novel.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Woods, Scott W — Yale University
- Study coordinator: Woods, Scott W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.